Coarsucam Antimalaria Amodiaquine Tablet for Malaria

Model NO.: DAWAALT001 Usage Mode: For external use State: Solid Type: Biological Products Name: Coarsucam Amodiaquine Tablet OEM: Acceptable Useage: Antimalaria Transport Package: 3+3/Blister/Box Origin: France Application: Internal Medicine Suitable for: Elderly, Children, Adult Shape: Tablet Pharmaceutical Technology: Chemical Synthesis Sample: Free Supply Caution: Consulting The Doctor Trademark: GUYENNE Specification: 200mg+200mg, 100mg+400mg, 50mg+135mg HS Code: 3004909099 Coarsucam Artesunat/Amodiaquine Tablet
Product Information of  Artesunat/Amodiaquine Tablet:
 

Specification:	200mg+200mg,100mg+400mg,50mg+135mg
Package:	3+3/blister/box

Introduction
amodiaquine (trade name Coarsucam) is a fixed-dose artemisinin-based combination therapy (ACT) indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria.
amodiaquine (AA) is one of two commonly used ACTs available, the other being artemisinin lumefantrine. AA is available in a number of formulations, including fixed-dose or co packaged. The efficacy of ACTs,artemisinin amodiaquine combination included in the treatment of uncomplicated malaria in malaria endemic regions is well documented.
It has its side effects, some of which could be lifethreatening. Among such are neutropenia, hepatitis and
fulminant hepatic failure , which may lead to hepaticencephalopathy, implying that amodiaquine therapy may affect the brain in ways that may not be envisaged at the commencement of therapy. Regardless of these possible risks, its affordability and efficacy make it important in the treatment of uncomplicated malaria. 

Medical uses
Amodiaquine has become an important drug in the combination therapy for malaria treatment in Africa.

Pharmacogenetics
It is bioactivated hepatically to its primary metabolite, N-desethylamodiaquine, by the cytochrome p450 enzyme CYP2C8. Among amodiaquine users, several rare but serious side effects have been reported and linked to variants in the CYP2C8 alleles. CYP2C8*1 is characterized as the wild-type allele, which shows an acceptable safety profile, while CYP2C8*2, *3 and *4 all show a range of "poor metabolizer" phenotypes. People who are poor metabolizers of amodiaquine display lower treatment efficacy against malaria, as well as increased toxicity.[5] Several studies have been conducted to determine the prevalence of CYP2C8 alleles amongst malaria patients in East Africa, and have tentatively shown the variant alleles have significant prevalence in that population.[6] About 3.6% of the population studied showed high risk for a poor reaction to or reduced treatment outcomes when treated with amodiaquine. This information is useful in developing programs of pharmacovigilance in East Africa, and have important clinical considerations for prescribing antimalarial medications in regions with high CYP2C8 variant frequency.

Contact us if you need more details on Antimalaria Drug. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Artemisinin、Pharmaceutical Chemical. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Antimalaria Drugs